Emerging Companies

858: Versant’s second start-up targeting RNA-modifying proteins

858 Therapeutics, the newest company targeting RNA-modifying proteins for oncology, will bring together a predecessor company, a veteran management team, and a deep-pocketed syndicate led by founding investor...

Anjarium: a hybrid approach to non-viral gene therapy

Switzerland-based Anjarium believes its platform using lipid nanoparticles and extracellular vesicles can help create non-viral gene therapies that can find a niche in the market, addressing challenges faced by others in the gene therapy sector....

Walking Fish launches to pioneer B cell therapies

Walking Fish emerged from stealth to join the ranks of new companies taking on cell therapy development, but it’s setting out to create an entirely new therapeutic modality in B cell therapies.  Nearly every major...

Wilson ventures into gene editing with iECURE launch, backed by $50M series A

Gene therapy pioneer James Wilson is expanding his entrepreneurial vision into gene editing with the launch of iECURE, a company tackling the challenging gene editing application of in vivo gene insertion. ...

Replicate: optimizing the promise of self-replicating RNA

Replicate is launching with a stable of optimized virally derived vectors to harness the dosing and safety advantages of self-replicating RNA. The start-up brings together several leaders in self-replicating RNA, also known as self-amplifying RNA,...

Through Versanis, Novartis vets raise $70M to pivot pharma’s muscle therapy to fat loss

With an eye toward endpoints that distinguish fat and muscle loss, Versanis aims to turn a Novartis mAb with underwhelming myositis data into an at-home obesity therapy. On Tuesday, Versanis Bio Inc. announced a $70...

Atavistik: Identifying allosteric modulators of metabolic proteins

Launching with a $60 million series A round, Atavistik is advancing an allosteric modulator discovery platform built on technology developed by Jared Rutter at the University of Utah. Rutter’s presentation at a meeting spurred The...

Immunitas: Strategics back $58M B round to push CD161 inhibitor into the clinic

With a $58 million B round in hand from a swath of new investors, Immunitas is aiming to push its first-in-class CD161 inhibitor into the clinic. Preclinical data give the company confidence that hitting...

Ranok: a chaperone-based approach to targeted degradation

An investor syndicate is backing Chinese biotech Ranok in a $40 million series B round that will allow the targeted protein degradation company to test its differentiated, chaperone-based approach in its first clinical trial. Hangzhou-based...

Bluejay: combining HBV therapies to reach a functional cure

Bluejay is applying a combination of therapies in-licensed from Novartis with an aim to cure chronic HBV by reducing viral surface antigen in both the liver and blood. Founder, Chairman and CEO Keting...

PepGen: $112.5M round for cell-penetrating oligos and a Boston build-out

With a fresh $112.5 million in crossover funding, PepGen is prepared to take at least two muscular dystrophy therapies into the clinic by 2023 and build out a new headquarters in Boston.  Thursday’s venture round...

Cytovia: activating NK cells at the tumor site

After bolstering its management team with new hires from BMS and AGTC, Cytovia is leveraging its two NK cell platforms and at least 11 partnerships to enter the clinic next year with therapies targeting solid...

PAQ: small molecules for autophagy-dependent degradation

With a July 15th $30 million series A round led by Sherpa Partners, PAQ joins a growing number of biotechs developing autophagy-dependent degraders that could push targeted degradation beyond protein substrates. ...

Hemab: $55M series A for Novo vets developing bispecific for rare bleeding disorders

Launched by a co-founding team that includes a pair of Novo Nordisk veterans, Hemab is advancing a bispecific antibody the pharma had de-prioritized with the goal of addressing rare bleeding disorders beyond hemophilia. Hemab ApS...

Rivus debuts to find safer way to tap mitochondria for metabolic, CV disorders

With an asset already in the clinic for metabolic disorders, two-year-old Rivus is putting $35 million from a syndicate led by Longitude and Medicxi toward development of small molecules that act in the mitochondrial intermembrane...